This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Cosentyx
  • /
  • A 52-week (Plus Extension Until Commercialization)...
Clinical trial

A 52-week (Plus Extension Until Commercialization), Single-arm Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI) at 16 Weeks, as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab A

Read time: 1 mins
Last updated:30th Apr 2015
Identifier: NCT02595970

Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered subcutaneously during 52 weeks (plus extension) in patients with moderate to severe psoriasis.


Category Value
Date last updated at source 2016-07-20
Study type(s) Interventional
Expected enrolment 120
Study start date 2015-05-01
Estimated primary completion date 2017-01-01